Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Fall;17(3):180-187.

Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review

Eric S Lee  1 , Misha M Heller  2 , Faranak Kamangar  3 , Kelly Park  4 , Wilson Liao  4 , John Koo  4
Affiliations

Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review

Eric S Lee et al. Psoriasis Forum. 2011 Fall.

Abstract

Hydroxyurea is a drug that has been long forgotten for the treatment of psoriasis. In addition to its anti-psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes it a drug that dermatologists may want to consider when treating psoriasis in HIV-infected individuals. There are currently no studies that discuss the safety and efficacy of hydroxyurea in the treatment of psoriasis in this immunocompromised group; however, there are multiple reports that discuss the safety and efficacy of hydroxyurea in psoriasis and HIV separately. This review suggests that hydroxyurea is generally safe and effective. The main risk involves the hematologic adverse events (anemia, leukopenia, thrombocytopenia, and macrocytosis) which appear to be dose-dependent. Because of the common hematologic adverse events, hydroxyurea may be considered as a viable therapeutic option for patients with generalized psoriasis inadequately responsive to other safer options, whether the patient is HIV-positive or not.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Garbe C, Husak R, Orfanos CE. HIV-associated dermatoses and their prevalence in 456 HIV-infected patients. Relation to immune status and its importance as a diagnostic marker. Hautarzt. 1994 Sep;45(9):623–9. - PubMed
    1. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol. 1987 Dec;123(12):1622–32. - PubMed
    1. Montazeri A, Kanitakis J, Bazex J. Psoriasis and HIV infection. Int J Dermatol. 1996 Jul;35(7):475–9. - PubMed
    1. Menon K, Van Voorhees AS, Bebo BF, Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010 Feb;62(2):291–9. Epub 2009 Jul 31. - PubMed
    1. Leavell UW, Jr, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol. 1970 Aug;102(2):144–50. - PubMed

LinkOut - more resources